Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor even with extensive surgery,
chemotherapy or radiation. It has been required development of new treatment modalities.
Immunotherapy is one of the encouraging modalities for cancer patients. The investigators
have to assess its toxicities and immune responsiveness.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicities as assessed by NCI-CACAE ver3
Mitsukazu Gotoh, MD & PhD
Fukushima Medical University, Department of Regeneration Surgery
Japan: Institutional Review Board